Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 9/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8567714 | 0.90 | MGMT (0.61) | MGMTLMNAPIN1PDE5AL3MBTL1 | |
| SCHEMBL311607 | 0.85 | MGMT (0.59) | MGMTLMNAPIN1PDE5AL3MBTL1 | |
| SCHEMBL311056 | 0.85 | MGMT (0.59) | MGMTLMNAPIN1L3MBTL1THRB | |
| SCHEMBL311450 | 0.84 | MGMT (0.57) | MGMTLMNAPIN1PDE5AL3MBTL1 | |
| SCHEMBL1232862 | 0.80 | L3MBTL1 (0.57) | MGMTLMNAPIN1PDE5AL3MBTL1 | |
| SCHEMBL8566311 | 0.79 | MGMT (0.61) | MGMTLMNAPIN1ELANE | |
| SCHEMBL17048021 | 0.79 | MGMT (0.60) | MGMTLMNAPIN1CNR1ACHE | |
| SCHEMBL3309544 | 0.78 | MGMT (1.00) | MGMTLMNAPIN1CDK1CCNB1 | |
| SCHEMBL4068099 | 0.76 | MGMT (0.76) | MGMTLMNAPIN1L3MBTL1CDK1 | |
| SCHEMBL8567582 | 0.76 | MGMT (0.48) | MGMTLMNAPIN1PDE5AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856254-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2016-09-29 | — | — | US | disclosed |
| US-9365567-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-06-14 | — | — | US | disclosed |
| EP-1673087-B1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20150023990-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-8871782-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8546383-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1658076-B1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8350034-B2 | Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-09-13 | — | — | US | disclosed |
| EP-1699792-A1 | PIPERAZINE, 1,4¨DIAZEPANE, 1,4¨DIAZOCANE, AND 1,5¨DIAZOCANE FUSED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006086633-A2 | SUBSTITUTED FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006083440-A2 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006074003-A2 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1673087-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1658076-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005032484-A9 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2005066172-A1 | PIPERAZINE, [1,4]DIAZEPANE, [1,4]DIAZOCANE, AND [1,5]DIAZOCANE FUSED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005032484-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005020999-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023990-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | MGMT 1076/4885LMNA 3758/4885PIN1 2458/4885 |
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | MGMT 1076/4885LMNA 3758/4885PIN1 2458/4885 |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | MGMT 4402/4885LMNA 2497/4885PIN1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.